Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL

EMBO Journal

Volumn 23, Issue 15, 2004, Pages 3051-3060

  Clarke, Nicole ^a   Jimenez Lara, Ana M ^a   Voltz, Emilie ^a   Gronemeyer, Hinrich ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Apoptosis; Interferon; IRF; Retinoic acid; Tumor suppressor

Indexed keywords

GAMMA INTERFERON; HISTONE; HISTONE ACETYLTRANSFERASE; INTERFERON; INTERFERON REGULATORY FACTOR 1; LIGAND; PROTEIN; RETINOIC ACID; RETINOID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CHROMATIN; COCULTURE; CONTROLLED STUDY; ERADICATION THERAPY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PARACRINE SIGNALING; PEPTIDE MAPPING; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; RECEPTOR OCCUPANCY; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON TYPE II; LEUKEMIA; MEMBRANE GLYCOPROTEINS; PHOSPHOPROTEINS; PROMOTER REGIONS (GENETICS); SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRETINOIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4143116932     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.emboj.7600302     Document Type: Article

References (66)

1. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, Riganelli D, Sebastiani C, Cappelli E, Casciari C, Sciurpi MT, Mariano AR, Minardi SP, Luzi L, Muller H, Di Fiore PP, Frosina G, Pelicci PG (2003) Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 112: 1751-1761
2. Almasan A, Ashkenazi A (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337-348
3. Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1: 181-193
4. Altucci L, Gronemeyer H (2004) Retinoids and TRAIL: two cooperating actors to fight against cancer. In Vitamins and Hormones, Litwack G (ed) Vol. 67, pp 319-345. Academic Press: Elsevier
5. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H (2001) Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 7: 680-686
6. Ashkenazi A, Dixit VM (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11: 255-260
7. Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP (2003) Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell 12: 627-637
8. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 119-134
9. Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27: 19-26
10. Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15: 749-795
11. Burns TF, El-Deiry WS (2001) Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 276: 37879-37886
12. Chen JY, Clifford J, Zusi C, Starrett J, Tortolani D, Ostrowski J, Reczek PR, Chambon P, Gronemeyer H (1996) Two distinct actions of retinoid-receptor ligands. Nature 382: 819-822
13. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356-1361
14. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998
15. Eason DD, LeBron C, Coppola D, Moscinski LC, Livingston S, Sutton ET, Blanck G (2003) Development of CD30 + lymphoproliferative disease in mice lacking Interferon regulatory factor-1. Oncogene 22: 6166-6176
16. Escalante CR, Yie J, Thanos D, Aggarwal AK (1998) Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. Nature 391: 103-106
17. Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T (1999) Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. EMBO J 18: 5028-5041
18. Germain P, Iyer J, Zechel C, Gronemeyer H (2002) Coregulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415: 187-192
19. Gong B, Almasan A (2000) Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 278: 747-752
20. Goyette P, Feng Chen C, Wang W, Seguin F, Lohnes D (2000) Characterization of retinoic acid receptor-deficient keratinocytes. J Biol Chem 275: 16497-16505
21. Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13: 95-109
22. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Altucci L, Gronemeyer H, Nervi C, Minucci S, Pelicci PG (2004) Inhibitors of histone deacetylases induce apoptosis selectively in leukemia cells through activation of the death receptor pathway. (submitted)
23. Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y, El-Deiry WS (2001) Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol 18: 241-247
24. Kolla V, Lindner DJ, Xiao W, Borden EC, Kalvakolanu DV (1996) Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem 271: 10508-10514
25. Laudet V, Gronemeyer H (2002) The Nuclear Receptor Facts Book. San Diego: Academic Press
26. Levy D, Reich N, Kessler D, Pine R, Darnell Jr JE (1988) Transcriptional regulation of interferon-stimulated genes: a DNA response element and induced proteins that recognize it. Cold Spring Harb Symp Quant Biol 53 (Part 2): 799-802
27. Lippman SM, Lotan R, Schleuniger U (1997) Retinoid-interferon therapy of solid tumors. Int J Cancer 70: 481-483
28. Matikaihen S, Ronni T, Hurme M, Pine R, Julkunen I (1996) Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood 88: 114-123
29. Matikainen S, Ronni T, Lehtonen A, Sareneva T, Melen K, Nordling S, Levy DE, Julkunen I (1997) Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ 8: 687-698
30. Melnick A, Licht JD (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215
31. Merika M, Williams AJ, Chen G, Collins T, Thanos D (1998) Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergisiic activation of transcription. Mol Cell 1: 277-287
32. Minucci S, Pelicci PG (1999) Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 10: 215-225
33. Morin P, Genin P, Doly J, Civas A (2002) The virus-induced factor VIF differentially recognizes the virus-responsive modules of the mouse IFNA4 gene promoter. J Interferon Cytokine Res 22: 77-86
34. Nebbioso A, Clarke N, Bontempo P, Volz E, Alvarez R, Schiavone EM, Weisz A, Bresciani F, de Lera AR, Gronemeyer H, Altucci L (2004) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. (submitted)
35. Nissen RM, Yamamoto KR (2000) The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 14: 2314-2329
36. Nozawa H, Oda E, Nakao K, Ishihara M, Ueda S, Yokochi T, Ogasawara K, Nakatsuru Y, Shimizu S, Ohira Y, Hioki K, Aizawa S, Ishikawa T, Katsuki M, Muto T, Taniguchi T, Tanaka N (1999) Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 13: 1240-1245
37. Ortiz MA, Bayon Y, Lopez-Hernandez FJ, Piedrafita FJ (2002) Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives. Drug Resist Update 5: 162-175
38. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, Pelicci PG (2000) PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207-210
39. Pelicano L, Li F, Schindler C, Chelbi-Alix MK (1997) Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action. Oncogene 15: 2349-2359
40. Percario ZA, Giandomenico V, Fiorucci G, Chiantore MV, Vannucchi S, Hiscott J, Affabris E, Romeo G (1999) Retinoic acid is able to induce interferon regulatory factor 1 in squamous carcinoma cells via a STAT-1 independent signalling pathway. Cell Growth Differ 10: 263-270
41. Piazza F, Gurrieri C, Pandolfi PP (2001) The theory of APL. Oncogene 20: 7216-7222
42. Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon JJ, van den Brink MR (2002) T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 8: 1433-1437
43. Sedger LM, Glaccum MB, Schuh JC, Kanaly ST, Williamson E, Kayagaki N, Yun T, Smolak P, Le T, Goodwin R, Gliniak B (2002) Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 32: 2246-2254
44. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H (2003) Nature's TRAIL - on a path to cancer immunotherapy. Immunity 18: 1-6
45. Sporn MB, Suh N (2002) Opinion: chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2: 537-543
46. Sun SY, Lotan R (2002) Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41: 41-55
47. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523
48. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K (2002) Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195: 161-169
49. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H, Okumura K (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol 214: 194-200
50. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ (2004) Induction of tumor-specific T Cell immunity by anti-DRS antibody therapy. J Exp Med 199: 437-448
51. Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, Matsuyama T, Mak TW, Taki S, Taniguchi T (1995) An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen- activated T lymphocytes. Nature 376: 596-599
52. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW, Taniguchi T (1994a) Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77: 829-839
53. Tanaka N, Ishihara M, Lamphier MS, Nozawa H, Matsuyama T, Mak TW, Aizawa S, Tokino T, Oren M, Taniguchi T (1996) Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 382: 816-818
54. Tanaka N, Ishihara M, Taniguchi T (1994b) Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. Cancer Lett 83: 191-196
55. Tanaka N, Kawakami T, Taniguchi T (1993) Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system. Mol Cell Biol 13: 4531-4538
56. Tanaka N, Taniguchi T (2000) The interferon regulatory factors and oncogenesis. Semin Cancer Biol 10: 73-81
57. Taneja R, Rochette-Egly C, Plassat JL, Penna L, Gaub MP, Chambon P (1997) Phosphorylation of activation functions AF-1 and AF-2 of RAR alpha and RAR gamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. EMBO J 16: 6452-6465
58. Thanos D, Maniatis T (1995) Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83: 1091-1100
59. Um SJ, Kim EJ, Hwang ES, Kim SJ, Namkoong SE, Park JS (2000) Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53. Int J Cancer 85: 416-423
60. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163
61. Wang Q, Ji Y, Wang X, Evers BM (2000) Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 276: 466-471
62. Wang S, El-Deiry WS (2003a) Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 100: 15095-15100
63. Wang S, El-Deiry WS (2003b) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633
64. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, Maniatis T (1998) Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol Cell 1: 507-518
65. Wu GS, Burns TF, McDonald III ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, el-Deiry WS (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17: 141-143
66. Xie RL, Gupta S, Miele A, Shiffman D, Stein JL, Stein GS, van Wijnen AJ (2003) The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. J Biol Chem 278: 26589-26596